New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 33, Issue 1, 2018, Pages 164-171

  Shimomura, Akira ^a   Nagata, Naoyoshi ^a   Shimbo, Takuro ^b   Sakurai, Toshiyuki ^a   Moriyasu, Shiori ^a   Okubo, Hidetaka ^a   Watanabe, Kazuhiro ^a   Yokoi, Chizu ^a   Akiyama, Junichi ^a   Uemura, Naomi ^c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b OHTA NISHINOUCHI HOSPITAL   (Japan)

^c National Center for Global Health and Medicine   (Japan)

Author keywords

acute gastrointestinal hemorrhage; direct oral anticoagulants (DOACs); proton pump inhibitors (PPIs); warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

AGED; ALL CAUSE MORTALITY; ARTICLE; CHA2DS2-VASC SCORE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIC ULCER; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; ACUTE DISEASE; CHEMICALLY INDUCED; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; STATISTICAL MODEL; TIME FACTOR;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK; RISK FACTORS; TIME FACTORS;

EID: 85039444577     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13830     Document Type: Article

References (35)

1. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013; 185: E121–E127.
2. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 2007; 167: 1414–1419.
3. Rondonotti E, Marmo R, Petracchini M, de Franchis R, Pennazio M. The American society for gastrointestinal endoscopy (ASGE) diagnostic algorithm for obscure gastrointestinal bleeding: eight burning questions from everyday clinical practice. Dig. Liver Dis. 2013; 45: 179–185.
4. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981–992.
5. Aoki T, Nagata N, Niikura R et al. Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. Clin. Gastroenterol. Hepatol. 2015; 13: 488 494.e1.
6. Marmo R, Koch M, Cipolletta L et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the italian PNED score and prospective comparison with the Rockall score. Am. J. Gastroenterol. 2010; 105: 1284–1291.
7. Irwin J, Ferguson R, Weilert F, Smith A. Supratherapeutic anticoagulation at presentation is associated with reduced mortality in nonvariceal upper gastrointestinal hemorrhage. Endosc. Int. Open. 2014; 2: E148–E152.
8. Halbritter K, Beyer-Westendorf J, Nowotny J, Pannach S, Kuhlisch E, Schellong SM. Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome. J. Thromb. Haemost. 2013; 11: 651–659.
9. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest 2010; 138: 1093–1100.
10. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J. Am. Coll. Cardiol. 2011; 58: 395–401.
11. O'Brien EC, Simon DN, Thomas LE et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur. Heart J. 2015; 36: 3258–3264.
12. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am. J. Gastroenterol. 2016; 111: 459–474.
13. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am. J. Gastroenterol. 2012; 107: 345,60 quiz 361.
14. Aoki T, Nagata N, Shimbo T et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin. Gastroenterol. Hepatol. 2016; 14: 1562 1570.e2.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
16. Peloquin JM, Seraj SM, King LY, Campbell EJ, Ananthakrishnan AN, Richter JM. Diagnostic and therapeutic yield of endoscopy in patients with elevated INR and gastrointestinal bleeding. Am. J. Med. 2016; 129: 628–634.
17. Niikura R, Nagata N, Aoki T et al. Predictors for identification of stigmata of recent hemorrhage on colonic diverticula in lower gastrointestinal bleeding. J. Clin. Gastroenterol. 2015; 49: e24–e30.
18. Niikura R, Yamada A, Nagata N et al. New predictive model of rebleeding during follow-up of patents with obscure gastrointestinal bleeding: a multicenter cohort study. J. Gastroenterol. Hepatol. 2016; 31: 752–760.
19. Kulkarni C, Moorthy S, Sreekumar K et al. In the workup of patients with obscure gastrointestinal bleed, does 64-slice MDCT have a role? Indian. J. Radiol. Imaging. 2012; 22: 47–53.
20. Nagata N, Niikura R, Aoki T et al. Role of urgent contrast-enhanced multidetector computed tomography for acute lower gastrointestinal bleeding in patients undergoing early colonoscopy. J. Gastroenterol. 2015; 50: 1162–1172.
21. Chan FK, Cryer B, Goldstein JL et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J. Rheumatol. 2010; 37: 167–174.
22. Nagata N, Niikura R, Yamada A et al. Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs: a multicenter case-control study. PLoS One 2016; 11 e0151332.
23. Nagata N, Niikura R, Sakurai T et al. Safety and effectiveness of early colonoscopy in management of acute lower gastrointestinal bleeding on the basis of propensity score matching analysis. Clin. Gastroenterol. Hepatol. 2016; 14: 558–564.
24. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996; 15: 361–387.
25. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
26. Chen WC, Chen YH, Hsu PI et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed. Res. Int. 2014; 2014: 463767.
27. Staerk L, Lip GY, Olesen JB et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015; 351: h5876.
28. Ray WA, Chung CP, Murray KT et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology 2016; 151: 1105 1112.e10.
29. Sherwood MW, Nessel CC, Hellkamp AS et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J. Am. Coll. Cardiol. 2015; 66: 2271–2281.
30. Laursen SB, Hansen JM, Hallas J, Schaffalitzky de Muckadell OB. The excess long-term mortality in peptic ulcer bleeding is explained by nonspecific comorbidity. Scand. J. Gastroenterol. 2015; 50: 145–152.
31. Chan EW, Lau WC, Leung WK et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015; 149: 586 95.e3.
32. Goodman SG, Wojdyla DM, Piccini JP et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J. Am. Coll. Cardiol. 2014; 63: 891–900.
33. Gerson LB. Causes of gastrointestinal hemorrhage in patients with chronic renal failure. Gastroenterology 2013; 145: 895 7; discussion 897.
34. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784–789.
35. Nagata N, Sakamoto K, Arai T et al. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int. J. Cancer 2014; 135: 2273–2281.